Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism
Benzinga Newsdesk 4 months ago
News
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint89% of patients completed the three-and-a-half-year trial
- Multi-organ system and quality-of-life benefits sustained through three and a half years
- 86% response rate for the multi-component endpoint
- 89% of patients completed the three-and-a-half-year trial